The Senate confirmed Erica Schwartz as director of the Centers for Disease Control and Prevention in a 51-44 vote, concluding a nearly yearlong vacancy for the agency’s top leadership role. Her confirmation makes Schwartz the second permanent CDC leader since the second Trump administration took office.
The leadership gap followed the firing of the CDC’s previous director last August by Health Secretary Robert F. Kennedy Jr. The absence of a permanent director allowed HHS to implement policy changes and operational shifts at the agency while the top post remained unfilled.
Schwartz takes charge as the CDC confronts multiple active public health threats. The article cites continuing measles transmission in the United States, a domestic foodborne parasitic outbreak with reported fatalities, and an Ebola outbreak in parts of Africa that has produced a large number of deaths. These outbreaks represent immediate operational priorities for the new director and will demand coordination of surveillance, prevention, and response activities.
During the CDC’s leadership vacancy, the Department of Health and Human Services moved to reduce the number of recommended pediatric vaccines without CDC leadership. Actions reported include delaying the hepatitis B birth dose and broader reductions in the childhood vaccine schedule. HHS also modified a CDC webpage to reverse the agency’s previous language that vaccines do not cause autism. Senate health committee leadership stated that HHS had agreed to modify that page again, though the article notes prior instances where promises from HHS leadership were not upheld.
These developments have placed the agency’s vaccine guidance and public messaging under close scrutiny and crystallized questions about how Schwartz will respond to an aggressive vaccine policy agenda from the health secretary.
At her Senate health committee confirmation hearing, Senator Bill Cassidy (R-La.) repeatedly questioned Schwartz about how she would withstand political pressure from Secretary Kennedy or former President Trump. The article reports that Cassidy seemed dissatisfied with her initial answers, but he ultimately voted to advance her nomination out of committee, saying he had spoken with her and was confident she knew what she was doing.
Cassidy warned that any reversal on agreements he had received from HHS to limit vaccine policy changes could complicate confirmations of future health nominees. The article also notes that Cassidy is leaving the Senate in January after losing his reelection bid, a political development that may alter the oversight landscape.
Schwartz is a retired rear admiral in the U.S. Public Health Service Commissioned Corps and previously served as deputy surgeon general during the first Trump administration. During that tenure, she was responsible for standing up Covid-19 public testing drive-thrus and tents — operational experience the article highlights as relevant to leading the agency through active outbreaks.
Her confirmation ends a prolonged leadership void at the CDC, but the article emphasizes unresolved questions about how Schwartz will manage the intersection of science-based public health practice and politically driven policy changes from HHS leadership. Observers will closely watch how she addresses current outbreaks, restores or reshapes vaccine recommendations and public communications, and defends the agency’s technical independence.
The piece also underscores the broader political context in which Schwartz assumes leadership: recent unilateral actions by HHS on vaccine policy, public controversy over the agency’s messaging on vaccine safety, and turnover among key congressional overseers. The article does not report specific plans Schwartz will pursue as director beyond the expectation that she will face immediate outbreak response responsibilities and high-stakes decisions about vaccine policy and agency integrity.